InvestorsHub Logo
Followers 32
Posts 491
Boards Moderated 0
Alias Born 10/11/2007

Re: Al4door post# 100396

Monday, 02/06/2017 10:32:56 AM

Monday, February 06, 2017 10:32:56 AM

Post# of 703452
To explain the latest press release, in simple terms, transparently, is that the trial is succeeding.

Their primary endpoint, Progression free survival, has the number of events necessary for the trail to be analyzed. Based on historical, data sets, regarding the length of time that it took to achieve the number of events, lead me to believe that this will be a statistically significant result favoring the experimental treatment arm.

Overall survival, nearly always takes longer to event out then does progression free survival.

It would appear that there still may be time to benefit from the low capitalization of the company at this time, Prior to more Data analysis and review.

It looks like they might be shooting for a ASCO presentation.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News